FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W217209087> ?p ?o ?g. }

• W217209087 abstract "Abstract Background Waldenströms macroglobulinemia (WM) is a lymphoplasmacytic subtype of Non-Hodgkins lymphoma in which specific molecular changes lead to unrestricted cell proliferation and overproduction of immunoglobulin-M. These processes require exquisite coordination between growth promoting transcription factors (NFkB) and cell homeostatic systems. The bioavailability of various transcription factors and cell cycle proteins is primarily regulated by the ubiquitin proteasome system (UPS). Moreover, the proteolytic machinery ensures proper elimination of unwanted or misfolded proteins, which when disrupted leads to protein accumulation and apoptotic cell death. The 26S proteasome is a barrel shaped structure with a 20S catalytic core that is flanked by 19S caps on either side. 26S proteasomes are critical for WM cell survival, which is clinically evident, as up to 80% of WM patients treated with the proteasome inhibitor (PI) bortezomib have derived significant benefit. Traditional PI such as bortezomib and carfilzomib have been designed to target the B5 catalytic core within the 26S proteasome. However, proteasomes are capable of altering conformation of their proteolytic subunits in response to inflammation and stress, which can lower the effectiveness of these PI. The 19S cap is the regulatory complex and functions in unfolding and deubiquitinating the proteins before their entry into the 20S complex using constitutive deubiquitinating enzymes (DUBS). Recently, it has been demonstrated that inhibition of the DUBS, UCHL5 and USP14 results in cell death in a variety of tumor types but more so in cancer cells that rapidly divide or have a high protein turnover rate. Aim To define the anti-WM activity of the novel DUB inhibitor, b-AP15 in preclinical models of WM. Methods The WM cell lines BCWM.1, RPCI-WM1 and MWCL-1 were used for experiments in this analysis. Proteasomal activity was measured using synthetic fluorogenic peptide substrates. Apoptosis was determined by annexin-V/PI staining and mitochondrial membrane permeability (MOMP) was assessed using TMRM followed by flow cytometry. Protein profiling was done via immunoblot analysis. Results As reported by D’Arcy et al in their characterization of the b-AP15 molecule, inhibition of UCHL5 and USP14 by b-AP15 does not disrupt proteasomal activity conferred by the b-catalytic subunits. We confirmed these findings by treating WM cells with single agent bortezomib (10nM), carfilzomib (10nM), b-AP15 (100nM) or all three agents in combination to assess chymotrypsin-like, caspase-like and trypsin-like proteasomal activity using fluorogenic peptide substrates. Further, when used in combination with the other PI, PI-mediated chymotrypsin-like activity remained inhibited in the presence of b-AP15. Next, we sought to determine if b-AP15 treatment could induce WM cell death. Annexin-v staining showed that b-AP15 (500uM) induced apoptosis in all WM cell lines (28 – 60% cell death) with variable responses noted among the 3 models. Treatment with b-AP15 increased MOMP while also inducing the cleavage of caspases-9 and 3 and PARP-1 suggesting that the anti-WM activity of b-AP15 is mediated through the intrinsic apoptotic pathway. As components of the NFkB signaling cascade lie downstream to the UPS, we examined the effects of b-AP15 on this pathway. When treated with the DUB-inhibitor, nuclear translocation of NFkB was reduced in a time dependent manner. Interestingly, treatment with b-AP15 increased the phosphorylation of the mitogen activated protein kinase-p38 (p38) in all the WM cell lines tested. Treatment of WM cells with b-AP15 in presence of the p38 inhibitor, SB203580, resulted in a synergistic induction of cell death. Conclusion b-AP15 is a novel DUB inhibitor that disrupts two regulatory enzymes (UCHL5 and USP14) present in the 19S proteasomal cap. Results presented here demonstrate that b-AP15 induces apoptosis in in vitro models of WM and with in vivo analysis underway, is a potential therapeutic in WM. We would like to acknowledge the Waterfall Waldenström Macroglobulinemia Research Fund, the Leukemia and Lymphoma Society and the International Waldenström Macroglobulinemia Foundation for their continued support. Disclosures: No relevant conflicts of interest to declare." @default.
• W217209087 created "2016-06-24" @default.
• W217209087 creator A5010286156 @default.
• W217209087 creator A5013974745 @default.
• W217209087 creator A5018113870 @default.
• W217209087 creator A5019040265 @default.
• W217209087 creator A5024309803 @default.
• W217209087 creator A5031537463 @default.
• W217209087 creator A5040141808 @default.
• W217209087 creator A5056820417 @default.
• W217209087 creator A5059729547 @default.
• W217209087 creator A5082720713 @default.
• W217209087 creator A5091287816 @default.
• W217209087 date "2013-11-15" @default.
• W217209087 modified "2023-10-01" @default.
• W217209087 title "Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To Waldenströms Macroglobulinemia Cells" @default.
• W217209087 doi "https://doi.org/10.1182/blood.v122.21.1823.1823" @default.
• W217209087 hasPublicationYear "2013" @default.
• W217209087 type Work @default.
• W217209087 sameAs 217209087 @default.
• W217209087 citedByCount "1" @default.
• W217209087 countsByYear W2172090872020 @default.
• W217209087 crossrefType "journal-article" @default.
• W217209087 hasAuthorship W217209087A5010286156 @default.
• W217209087 hasAuthorship W217209087A5013974745 @default.
• W217209087 hasAuthorship W217209087A5018113870 @default.
• W217209087 hasAuthorship W217209087A5019040265 @default.
• W217209087 hasAuthorship W217209087A5024309803 @default.
• W217209087 hasAuthorship W217209087A5031537463 @default.
• W217209087 hasAuthorship W217209087A5040141808 @default.
• W217209087 hasAuthorship W217209087A5056820417 @default.
• W217209087 hasAuthorship W217209087A5059729547 @default.
• W217209087 hasAuthorship W217209087A5082720713 @default.
• W217209087 hasAuthorship W217209087A5091287816 @default.
• W217209087 hasConcept C102658986 @default.
• W217209087 hasConcept C104317684 @default.
• W217209087 hasConcept C185592680 @default.
• W217209087 hasConcept C203014093 @default.
• W217209087 hasConcept C25602115 @default.
• W217209087 hasConcept C27740335 @default.
• W217209087 hasConcept C2776364478 @default.
• W217209087 hasConcept C2777478702 @default.
• W217209087 hasConcept C2778367456 @default.
• W217209087 hasConcept C2780108899 @default.
• W217209087 hasConcept C502942594 @default.
• W217209087 hasConcept C55493867 @default.
• W217209087 hasConcept C86339819 @default.
• W217209087 hasConcept C86803240 @default.
• W217209087 hasConcept C95444343 @default.
• W217209087 hasConceptScore W217209087C102658986 @default.
• W217209087 hasConceptScore W217209087C104317684 @default.
• W217209087 hasConceptScore W217209087C185592680 @default.
• W217209087 hasConceptScore W217209087C203014093 @default.
• W217209087 hasConceptScore W217209087C25602115 @default.
• W217209087 hasConceptScore W217209087C27740335 @default.
• W217209087 hasConceptScore W217209087C2776364478 @default.
• W217209087 hasConceptScore W217209087C2777478702 @default.
• W217209087 hasConceptScore W217209087C2778367456 @default.
• W217209087 hasConceptScore W217209087C2780108899 @default.
• W217209087 hasConceptScore W217209087C502942594 @default.
• W217209087 hasConceptScore W217209087C55493867 @default.
• W217209087 hasConceptScore W217209087C86339819 @default.
• W217209087 hasConceptScore W217209087C86803240 @default.
• W217209087 hasConceptScore W217209087C95444343 @default.
• W217209087 hasLocation W2172090871 @default.
• W217209087 hasOpenAccess W217209087 @default.
• W217209087 hasPrimaryLocation W2172090871 @default.
• W217209087 hasRelatedWork W1568032496 @default.
• W217209087 hasRelatedWork W161994666 @default.
• W217209087 hasRelatedWork W1978493491 @default.
• W217209087 hasRelatedWork W2015883486 @default.
• W217209087 hasRelatedWork W2018532987 @default.
• W217209087 hasRelatedWork W2045926926 @default.
• W217209087 hasRelatedWork W2056769035 @default.
• W217209087 hasRelatedWork W2089604938 @default.
• W217209087 hasRelatedWork W2102559648 @default.
• W217209087 hasRelatedWork W2115443599 @default.
• W217209087 hasRelatedWork W2153294454 @default.
• W217209087 hasRelatedWork W2154919747 @default.
• W217209087 hasRelatedWork W2206692498 @default.
• W217209087 hasRelatedWork W2282199930 @default.
• W217209087 hasRelatedWork W2298892039 @default.
• W217209087 hasRelatedWork W2314099667 @default.
• W217209087 hasRelatedWork W2566461543 @default.
• W217209087 hasRelatedWork W2567996398 @default.
• W217209087 hasRelatedWork W2582043129 @default.
• W217209087 hasRelatedWork W2980225243 @default.
• W217209087 isParatext "false" @default.
• W217209087 isRetracted "false" @default.
• W217209087 magId "217209087" @default.
• W217209087 workType "article" @default.